S
688293
vs
S
Shanghai Composite
Over the past 12 months, Shanghai OPM Biosciences Co Ltd has underperformed Shanghai Composite, delivering a return of +26% compared to the Shanghai Composite's +28% growth.
Stocks Performance
688293 vs Shanghai Composite
Performance Gap
688293 vs Shanghai Composite
Performance By Year
688293 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Shanghai OPM Biosciences Co Ltd
Glance View
Shanghai OPM Biosciences Co. Ltd. engages in the cell culture products and services. The company is headquartered in Shanghai, Shanghai and currently employs 261 full-time employees. The company went IPO on 2022-09-02. The firm's cell culture medium products are widely used in the manufacturing of protein, antibiotics, vaccine, cell therapy products, gene therapy products, and other biological products. The firm's contract development and manufacturing organization (CDMO) service platform provides comprehensive services covering antibody engineering humanized screening, cell strain cultivation, process development, pilot scale production, and clinical-stage sample production. The firm conducts businesses both in the domestic market and overseas markets.
